AveXis Announces Potential Price for IPO
AveXis expects to price more than 4 million shares in the range of $19 to $21 in an initial public offering valued at up to more than $102 million.
All Work
Chris Lange
Why the LoJack Acquisition Is an Absolute Win for Shareholders
Under the terms of the deal, CalAmp will acquire all of the outstanding shares of common stock of LoJack in an all cash transaction valued at approximately $134 million.
Integrated Device Tech Falls Despite Earnings Meet
Integrated Device Technology released its fiscal third-quarter financial results after the markets closed on Monday.
How Michael Kors Knocked Earnings out of the Park
Michael Kors reported better-than-expected fiscal third-quarter financial results before the markets opened on Tuesday.
How Mattel Beat Earnings
Mattel reported better-than-expected fourth-quarter financial results after the markets closed on Monday.
Alphabet Passes Apple as Largest Market Cap After Earnings
While Alphabet is not in all of the same operations as Apple, Monday was critical for Apple's status as the largest company in the world.
What to Look for in Exxon’s Earnings Report
Exxon Mobil is expected to release its fourth-quarter earnings before the markets open on Tuesday.
What to Expect From Pfizer Earnings
Pfizer is scheduled to report its fourth-quarter financial results before the markets open on Tuesday.
Advanced Disposal Services Announces Potential IPO Pricing
Advanced Disposal Services shares are expected to price in the range of $20 to $22 per share, valuing the initial public offering at roughly $500 million.
PLx Pharma Gets Closer to IPO Debut
More than 3 million PLx Pharma shares are expected to price in the range of $17 to $19 per share in an initial public offering valued up to about $83 million.
Neos Therapeutics Gears Up for Secondary Offering
Neos Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering.
Could This Be the Turning Point for TrovaGene?
Despite being a small medical laboratory and research firm, TrovaGene offered cover for investors in Monday's session from a downturn in the broad markets.
Is Alere Really Worth the 50% Premium?
Alere absolutely skyrocketed in Monday’s regular session following the announcement that it will be acquired by Abbott Laboratories.
What to Expect From Alphabet Earnings
Alphabet is scheduled to report its fourth-quarter financial results after the markets close on Monday.
Exelixis Rises on Positive Late-Stage Trial Results
Exelixis shares were rising early Monday following the release of positive results from its late-stage trial of cabozantinib.
How Analysts See Qualcomm After Earnings
A couple of key analysts weighed in on the semiconductor giant Qualcomm after its fiscal first-quarter earnings report.
3 Key FDA Decisions Expected in February
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.
How Analysts See Juniper Networks After a Bad Earnings Reaction
Juniper Networks cratered following the release of its fourth-quarter earnings last week. As a result, the company was hit with a barrage of analyst calls, mostly cutting the price target.
Top 3 Dow Earnings for the Coming Week
24/7 Wall St. has put together a preview of the three Dow Jones Industrial Average companies that are reporting their quarterly results this week.
Are Analysts and Investors Getting Too Down on eBay?
As a result analysts piled on to the stock, but they may have been overly negative, considering the earnings report.